Description:

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01258192

Link:

https://clinicaltrials.gov/show/NCT01258192

Keywords:
Versions (1) ▾
  1. 12/14/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

December 14, 2019

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Esophageal Squamous Cell Carcinoma NCT01258192

Eligibility Esophageal Squamous Cell Carcinoma NCT01258192

Inclusion Criteria
histologic diagnosis of squamous cell carcinoma of esophagus. preoperative stage ⅱ-ⅲ
by endoscopic ultrasound, ct of the chest and abdomen,and esophagogram.
age ranges from 18 to 70 years.
patients must not have received any prior anticancer therapy.
performance status of 0 to 1
estimated life expectancy of at least 6 months.
tumor can be measured according to recist criteria
signed informed consent document on file.
females with childbearing potential must have a negative serum pregnancy
adequate organ function including the following:
bone marrow: absolute neutrophil count (anc) greater than or equal 1.5×109/l platelets greater than or equal 80×109/l haemoglobin greater than or equal 80g/l hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (uln), alanine transaminase (alt) and aspartate transaminase (ast) less than or equal to 2.5 times uln renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment.
Exclusion Criteria
carcinoma at the upper part of esophagus
histologic diagnosis of adenocarcinoma of esophagus.
prior treatment for esophageal cancer.
active infection.
pregnant or breast feeding.
history of significant neurological or mental disorder, including seizures or dementia.
prior invasive malignancy in 5 years (except for carcinoma in situ).